Les inhibiteurs des récepteurs de l’Epidermal Growth Factor (EGF)
- 30 June 2003
- journal article
- review article
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 24 (6) , 372-383
- https://doi.org/10.1016/s0248-8663(03)00060-2
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibodyInternational Journal of Cancer, 2002
- Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growthAnnals of Oncology, 2002
- Replacement of N‐terminal portions of TGF‐α with corresponding heregulin sequences affects ligand‐induced receptor signaling and intoxication of tumor cells by chimeric growth‐factor toxinsInternational Journal of Cancer, 2001
- Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)Lung Cancer, 2000
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- ZD1839 (???Iressa???)*,??? as an Anticancer AgentDrugs, 2000
- Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomasEuropean Journal Of Cancer, 1996
- Signal transduction by receptors with tyrosine kinase activityPublished by Elsevier ,1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989